ZAPATA LARRAIN, RODRIGO
Preferred name
ZAPATA LARRAIN, RODRIGO
Official Name
ZAPATA LARRAIN, RODRIGO
Main Affiliation
Email
rzapata@udd.cl
ORCID
0000-0001-6050-0363
Scopus Author ID
7006909968
32 results
Now showing 1 - 10 of 32
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The Spectrum of De novo Malignancies After Liver Transplantation: A Review on Current Trends and SurveillanceAbstract: Over the last few decades, advances in liver transplantation (LT) have consistently improved patient survival, providing recipients with longer life expectancy and better quality of life. However, patients undergoing prolonged immunosuppression face an increased risk of de novo malignancies (DNMs) due to the oncogenic effects of immunosuppressive drugs and other established risk factors. These include chronic viral infections, sun exposure, smoking, the underlying etiology of liver disease (such as alcoholic liver disease and primary sclerosing cholangitis), and various biodemographic factors, including age, body weight, lifestyle choices, and ethnicity. As a result, DNMs have become one of the leading causes of late mortality among LT recipients, accounting for 20– 25% of post-transplant deaths. Nonmelanoma skin cancers are the most common DNMs, representing 35–40% of cases, with a cumulative risk 10–20 times higher than that of age- and sex-matched individuals in the general population. Post-transplant lymphoproliferative disorders (PTLD) are the second most frequent DNMs, particularly prevalent in pediatric recipients (5–20% of total DNMs), and are associated with significantly lower survival rates. Solid organ tumors, which account for 40–50% of DNMs, primarily involve the lung, head and neck, and colorectal sites, and demonstrate a two- to threefold higher incidence and more aggressive progression compared to the general population. The development of solid organ DNMs has a major impact on long-term outcomes following LT, highlighting the need for updated reviews focused on prevention and management. The increased incidence of DNMs in LT recipients underscores the importance of minimizing immunosuppressive therapy, stratifying patients according to cancer risk, implementing early protective strategies (such as reducing exposure to known risk factors), and establishing tailored, costeffective long-term screening protocols to detect malignancies at an early stage. Early detection enables timely treatment, ultimately improving long-term survival and quality of life. Future prospective studies are needed to optimize and validate surveillance strategies for this high-risk population. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, AMA-NEGATIVE PRIMARY BILIARY CHOLANGITIS IN LATIN AMERICA: A DISTINCT SUBSET WITH LOWER TREATMENT RESPONSE(Elsevier BV, 2025-09) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Latin American association for the study of the liver (ALEH) guidance on preoperative care in liver transplantation: referral criteria, patient assessment, and waiting list management(Elsevier BV, 2025-07); Luis Antonio Díaz3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, MELD 3.0 PERFORMANCE: EXTERNAL VALIDATION IN A LATIN AMERICAN TRANSPLANT LIVER COHORT(Elsevier BV, 2025-09) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, FIBRATES SEEM TO BE EQUALLY EFFECTIVE AS SECOND-LINE THERAPY IN PRIMARY BILIARY CHOLANGITIS, WITH BIOCHEMICAL RESPONSE PLATEAUING AT 6 MONTHS(Elsevier BV, 2025-09) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 9